PP12 PREVALENCE AND RISK FACTORS OF METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN CHRONIC OBSRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN A TERTIARY RESPIRATORY CENTRE IN MALAYSIA

Muhammad Bakhiit Ahmad Sabri^1,Thevaarajan Jayaraman^1,Aisya Natasya Musa¹^,Rafiz Abdul Rani¹

Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh, Selangor, Malaysia¹

Introduction
Metabolic associated fatty liver disease (MAFLD) and chronic obstructive pulmonary disease (COPD) both carry significant health burdens. In COPD patients, systemic inflammation, fat tissue inflammation, and long-term steroid use may contribute to the development of MAFLD.

Objective
To determine the prevalence of MAFLD and liver fibrosis in COPD patients via transient elastography, and the factors associated between MAFLD and COPD.

Methodology
In this cross-sectional study conducted at a tertiary centre, COPD patients who fulfilled inclusion criteria were enrolled and subjected to spirometry and transient elastography measurement in addition to routine demographic, clinical and biochemical evaluation. COPD symptom burden was assessed using COPD Assessment Tool (CAT) questionnaire. Liver stiffness measurement (LSM) and Controlled Attenuated

Parameter (CAP) were obtained via transient elastography.

Results
70 patients were recruited in the study. The mean age years was 70.69 (±9) with majority of the patients were male (95.7%) and Malay (90%). The prevalence of MAFLD in COPD was 67.1% and the prevalence of liver fibrosis within the COPD MAFLD population was 38.6%. High BMI was found to be a significant risk factor for MAFLD in COPD, compared to individuals with normal BMI, overweight and obese individuals had higher odds of having MAFLD (OR= 6.33, 95% CI 1.79-22.39, P=0.004)

Conclusion
This is the first local study to assess prevalence of MAFLD and liver fibrosis in COPD patients. It found a high prevalence, especially in overweight or obese individuals. There is also high prevalence of liver fibrosis within MAFLD population. This highlights the need for routine screening as early detection which can allow holistic management to be offered to improve the burden of disease and prevent disease progression.